Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection |
| |
| Affiliation: | 1. Lund University, Department of Translational Medicine, Malmö, Sweden;2. University of Oxford, Nuffield Department of Medicine, Oxford, UK;3. Karolinska Institute, Microbiology, Tumor and Cell Biology, Stockholm, Sweden;4. Landspitali University Hospital, Department of Virology, Reykjavik, Iceland;5. University of Iceland, Faculty of Medicine, School of Health Sciences, Reykjavik, Iceland;6. Landspitali University Hospital, Department of Infectious Diseases, Reykjavik, Iceland;1. Department of Medicine, University of California, San Francisco, CA 94158, USA;2. Department of Public Health, San Francisco, CA 94102, USA;3. Department of Epidemiology and Biostatistics, University of California, San Francisco 94158, USA;1. Department of Clinical and Laboratory Genetics, Medical University of Lodz, 251 Pomorska St., 92-213 Lodz, Poland;2. Department of Ophthalmology, University of California San Diego, 9500 Gillman Dr, La Jolla, CA 92093-0718, United States;3. Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, 62 Pabianicka St., 93-513 Lodz, Poland;4. GeneaMed LTD, 16/18/904 Kopcinskiego St., 90-232 Lodz, Poland;5. Department of Computer Engineering, Wroclaw University of Technology, 11/17 Janiszewskiego St., 50-372 Wroclaw, Poland;6. Leibniz Institute of Polymer Research Dresden, Hohe Str. 6, D-01069 Dresden, Germany;7. Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 62 Pabianicka St., 93-513 Lodz, Poland;8. Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., 90-236 Lodz, Poland |
| |
| Abstract: | BackgroundWhile vaccine-induced antibodies are known to confer protection against incident human papillomavirus (HPV) infection, there is inconsistent data regarding the protective effect of naturally acquired anti-HPV antibodies.ObjectivesTo estimate the protective effect of naturally acquired anti-HPV16 serum antibodies against incident anogenital infection with HPV16 in females aged 20–64 years and to assess whether antibodies influence the persistence/clearance of anogenital HPV16 infection.Study design4432 women attending the organized national cervical cancer screening program in Slovenia were initially enrolled. 2199 and 1848 women had valid HPV DNA results obtained using PCR-based assays and HPV antibody serotyping results obtained using pseudovirion-based serological assay, at baseline and at three-year follow-up, respectively.ResultsBaseline HPV16 seroprevalence was 2.4-fold higher among HPV16 DNA-positive women (55.7% vs. 23.2%; p < 0.01). Baseline HPV16 DNA-positive/seronegative women frequently acquired anti-HPV16 antibodies during follow-up (OR = 8.2; 95% CI: 3.8–17.8). Baseline anti-HPV16 antibodies persisted at follow-up, irrespective of baseline HPV16 DNA status (OR = 40.6; 95% CI: 30.3–54.5). Baseline HPV16 DNA-negative/seropositive women were less likely to acquire HPV16 infection at follow-up (unadjusted OR = 0.2; 0.1–0.9). However, the age-adjusted association was non-significant (adjusted OR = 0.3; 0.1–1.2). The tendency for protective effect was stronger among women older than 25 years (OR = 0.2; 0.03–1.8). Baseline anti-HPV16 antibodies were not associated with persistence/clearance of HPV16 infection at follow-up (OR = 0.8; 0.3–1.9).ConclusionsNaturally acquired anti-HPV16 serum antibodies appeared to protect against anogenital HPV16 infection, but this association was at least partially confounded by age. Baseline anti-HPV16 serum antibodies did not influence persistence/clearance of HPV16 infection at follow-up. |
| |
| Keywords: | Human papillomaviruses Cervical cancer HPV16 Serum antibodies |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
